NVCT Nuvectis Pharma, Inc.
$18.32▼ -0.65%
Healthcare
Other
Volume 93.9K
Avg Volume (10D) 173.2K
Key Metrics & Fundamentals
Market Cap
$598.04M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.55 - 29.28
% vs 50 MA
-14.99%
% vs 200 MA
27.52%
RSI-14
40.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.88
Free Cash Flow
-$4.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$7.20M
COGS
–
Operating Exp
$7.20M
Operating Income
-$7.20M
EBIT
-$7.20M
Pretax Income
-$7.02M
Net Income
-$7.02M
EPS (Diluted)
-0.30
Price & Volume History
Loading chart…
Recent News
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
GlobeNewswire · Oct 26, 2026 8:30 AM ET
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
GlobeNewswire · Oct 9, 2026 8:00 AM ET
Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma
MT Newswires · Sep 24, 2026 8:37 AM ET
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
GlobeNewswire · Sep 24, 2026 8:00 AM ET
Nuvectis Pharma To Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 8:00 AM ET
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Zacks · Aug 19, 2026 11:33 AM ET
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire · Aug 4, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NVCT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.